Careers  |  Sign In  |  Register  |   Twitter

Diabetes Drug Linked to Greater Risk of Heart Failure

Reuters reports that an article in NEJM has identified possible negative side effects for the approved diabetes drug, Onglyza. Onglyza is a DPP-4 therapy, which blocks dipeptidyl peptidase to help enhance the body’s ability to lower blood sugar levels. In the study, when compared to controls, Onglyza “did not increase or decrease the rates of ischemic events.” However, it did lead to increases in hospitalizations due to heart failure, or the inability of the heart to adequately pump blood. Scientists from AstraZeneca and Bristol-Myers Squibb, the manufacturers of Onglyza, claim that this effect is small and may be common to all DPP-4 therapies.

Read the article published by Reuters.

Read the study in NEJM.